2

Variation in the prevalence of respiratory symptoms, respiratory disease, sensitization, bronchial responsiveness, exposure and antiasthmatic treatment in the European Community Respiratory Health Servey

CentresMedianRangeReference
Symptoms
 Wheeze4820.74.1–32.0 17
 Waking with breathlessness477.31.5–11.4 17
 Waking with cough4827.96.0–42.6 17
Asthma and rhinitis
 Current asthma (stage 1)484.52.0–11.9 17
 Current asthma (stage 2)345.21.2–13.0 17
 Nasal allergy and hay fever4520.99.5–40.9 17
Bronchial responsiveness
 PD20≤1 mg3513.03.4–27.8 18
 ECRHS slope (mean)357.66.7–8.4 18
Allergic sensitization
 Mite3520.36.7–35.1 19
 Cat358.52.7–14.8 19
 Timothy3518.08.1–34.6 19
 Cladosporium352.40.3–13.6 19
 Any allergen3533.116.2–44.5 19
 IgE (geometric mean) kU·L−13535.913.2–62.2 19
Exposure
 Male smokers*343817–65 14
 Female smokers*343314–52 14
 Gas stoves3463.00–100 73
 Cat ownership3520.13.7–68.6 38
Heredity
 Asthma prevalence in parents305.83.4–10.6 87
Treatment
 Asthma medication (stage 1)483.59.6–9.8 17
 Inhaled bronchodilators344.60.7–12.4 20
 Inhaled anti-inflammatory drugs342.80.3–8.2 20
 Oral antiasthmatics341.40.2–6.5 20
  • PD20: provocative concentration causing a 20% fall in forced expired volume in one second

  • IgE: immunoglobalin-E

  • *: subjects with asthma excluded